This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Illumina (ILMN) Preliminary Q1 Revenues Rebound, '21 View Up
by Zacks Equity Research
Illumina's (ILMN) revenue improvement in the first quarter is likely to have been boosted by on-going business recovery.
Here's Why You Should Hold on to Bruker (BRKR) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Bruker (BRKR) on its slew of product launches and potential in the BSI Nano Group.
Quest Diagnostics (DGX) Divests Minority Share of Q2 Solutions
by Zacks Equity Research
Quest Diagnostics' (DGX) divestment of Q2 solutions to IQVIA will allow IQVIA to lead Q2 Solutions on the next stage of its journey in central lab services as a global leader.
Henry Schein's (HSIC) New Deal Boosts Ambulatory Surgery Market
by Zacks Equity Research
Henry Schein's (HSIC) recent majority ownership in Stradis Healthcare will advance the former's commitment to offer specialty solutions to customers.
Integra's (IART) Neurosurgery Rebounds Despite Supply Issues
by Zacks Equity Research
Integra LifeSciences (IART) is confident of achieving long-term goals of 5% to 7% revenue growth organically,
Illumina's (ILMN) Grail Merger in Trouble as FTC Files Suit
by Zacks Equity Research
According to FTC, the Illumina (ILMN) and Grail merger will diminish the scope of innovation in the U.S. market for MCED tests.
Surging Earnings Estimates Signal Upside for Dentsply (XRAY) Stock
by Zacks Equity Research
Dentsply (XRAY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Why You Should Add DENTSPLY SIRONA (XRAY) to Your Portfolio
by Zacks Equity Research
Investor confidence is high in the DENTSPLY SIRONA (XRAY) stock, thanks to solid prospects.
DENTSPLY SIRONA's (XRAY) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in DENTSPLY SIRONA (XRAY).
Here's Why You Should Retain Cooper Companies (COO) Now
by Zacks Equity Research
Investors remain optimistic about Cooper Companies (COO) backed by strong CSI and CVI product portfolios and its continued leadership in the specialty lenses market.
Zacks Industry Outlook Highlights: McKesson Corp, West Pharmaceutical Services, Cardinal Health, Align Technology and Dentsply Sirona
by Zacks Equity Research
Zacks Industry Outlook Highlights: McKesson Corp, West Pharmaceutical Services, Cardinal Health, Align Technology and Dentsply Sirona
3 Stocks to Capitalize on Promising Dental Supplies Industry
by Trina Mukherjee
Despite the challenges thrown by the COVID-19 pandemic, teledentistry coupled with AI & Robotics should lend support to the Zacks Medical - Dental Supplies industry. MCK, WST and CAH are well-poised to gain from the prospects.
DENTSPLY SIRONA (XRAY) at a 52-Week High: What's Driving It?
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) is optimistic about growth in CAD/CAM business arm along with its recent product launch and strategic buyouts.
DENTSPLY SIRONA (XRAY) Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) witnesses consumable revenue growth in the fourth quarter.
Why Earnings Season Could Be Great for DENTSPLY (XRAY)
by Zacks Equity Research
DENTSPLY (XRAY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Thermo Fisher (TMO) Rides on Pharma & Biotech Amid Pandemic
by Zacks Equity Research
Customers in Thermo Fisher's (TMO) industrial and applied end markets get affected by business disruptions due to the pandemic.
What's in Store for Fulgent Genetics (FLGT) in Q4 Earnings?
by Zacks Equity Research
We expect strong demand for Fulgent Genetics' (FLGT) end-to-end tests for COVID-19 to have continued through the fourth quarter.
Integra (IART) Arms Grow Sequentially Despite Supply Issues
by Zacks Equity Research
Integra LifeSciences (IART) is confident of achieving long-term goals of 5% to 7% revenue growth organically.
DENTSPLY SIRONA (XRAY) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) fourth-quarter results are likely to reflect weak segmental performance.
Bruker (BRKR) Rides on Product Launches Amid COVID-19 Woes
by Zacks Equity Research
Within Bruker's (BRKR) Nano Group Semiconductor metrology revenues have been steady with order rates improving as semi metrology equipment markets are witnessing a rebound.
Dentsply International (XRAY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Dentsply (XRAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 Medical Products Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Rebound in sales volumes and rise in COVID-19 support products sales make us optimistic about MDT, MASI, XRAY and COO's results.
LabCorp's (LH) New Antigen Test to Spot Active COVID-19 Virus
by Zacks Equity Research
LabCorp's (LH) new antigen test is the newest development to detect COVID-19 infection at every single stage, from diagnostic testing to vaccination trails.
Medtronic (MDT) Progresses in SNM With Updated InterStim Label
by Zacks Equity Research
Medtronic (MDT) expects this updated labeling with wider procedural options and shorter wait time to improve patient access to MRI exams and add more flexibility for MRI providers.
Owens & Minor (OMI) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
We expect the strength in demand for Owens & Minor's (OMI) PPEs to have continued through the fourth quarter.